Bristol-Myers Beats the Drum for Celgene in 4Q18 Earnings Call
Bristol Myers Squibb Co (BMY US) announced earnings for 4Q18 this morning followed by a conference call. Most metrics beat street expectations but...
1.2k Views
Amarin--2019's Biggest Buyout Target for Big Pharma
Amarin (AMRN US), a US-listed biotech firm, presented the full results of its "Reduce-It" (RI) clinical trial at a conference for the American...
4.9k Views
Junshi Biosciences IPO Preview: A Sense of Déjà Vu Without the Excitement
Shanghai Junshi Bioscience Co. Ltd. (1387344D CH) is a biopharmaceutical company which is developing a pipeline of 13 biologic drugs, including...
566 Views
Kyorin 1H FY18 (YE Mar'19) Results - First Glance
Key highlights Overall sales (¥50b) stayed flat as brisk uptake of Flutiform (+13% to ¥6.1b), Desalex (+200% to ¥2.8b) and Nasonex (after Merck...
443 Views
Eisai 1H FY18 (YE Mar'19) Results - First Glance
Key highlights Lenvima, Eisai’s key revenue driver, performed across regions (+43% to ¥14.3b in the US, +170% to ¥4.3b in Japan and +40% to ¥3.7b...
516 Views